Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Autor: Bekir Hacioglu, Kostek, Osman, Karabulut, Senem, Tastekin, Didem, Goksu, Sema Sezgin, Alandag, Celal, Akagunduz, Baran, Bilgetekin, Irem, Caner, Burcu, Sahin, Ahmet Bilgehan, Yildiz, Birol, Kose, Fatih, Kaplan, Muhammet Ali, Gulmez, Ahmet, Dogan, Ender, Guven, Deniz Can, Gurbuz, Mustafa, Ergun, Yakup, Karaagac, Mustafa, Demiray, Atike Gokcen, Turker, Sema, Sakalar, Teoman, Ozkul, Ozlem, Telli, Tugba Akin, Sahin, Suleyman, Kilickap, Saadettin, Bilici, Ahmet, Erdogan, Bulent, Cicin, Irfan
Jazyk: angličtina
Rok vydání: 2020
Předmět:
cancer patient
Turkey
Pyridines
Hepatocellular carcinoma
alpha fetoprotein
retrospective study
Anti-VEGF Therapy
cisplatin
Turkey (republic)
fluorouracil
systemic therapy
cancer control
Disease Control Rate
advanced cancer
cancer survival
Disease controlrate
Regorafenib
progression free survival
Overall Survival
adult
Liver Neoplasms
gemcitabine
Middle Aged
aged
female
drug substitution
drug withdrawal
alpha fetoprotein blood level
liver cell carcinoma
Carcinoma
Hepatocellular
Anti-VEGFtherapy
liver cirrhosis
overall survival
Overallsurvival
anthracycline
Article
cancer chemotherapy
male
cancer combination chemotherapy
x-ray computed tomography
Humans
Chemotherapy
follow up
metastasis
controlled study
human
Retrospective Studies
treatment duration
median survival time
Phenylurea Compounds
oxaliplatin
treatment response
Hepatocellular Carcinoma
tumor invasion
major clinical study
digestive system diseases
drug efficacy
sorafenib
drug hypersensitivity
Zdroj: Scopus-Elsevier
Web of Science
Popis: Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the second- or third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a second- or third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (pPFS=0.22 and pOS=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. © 2020 Zerbinis Publications. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: